Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Makoto Kanebako is active.

Publication


Featured researches published by Makoto Kanebako.


European Journal of Pharmaceutics and Biopharmaceutics | 2010

Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide

Hiroshi Miura; Makoto Kanebako; Hiroyuki Shirai; Hiroshi Nakao; Toshio Inagi; Katsuhide Terada

The aim of this study was to enhance the dissolution rate and oral absorption of a poorly water-soluble drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one (K-832) by adsorbing it onto the porous silica Sylysia 350 using supercritical CO(2) (scCO(2)) as a solvent. K-832-silica formulations were prepared using scCO(2) or dichloromethane (DCM) as the solvent (K-832-silica scCO(2) and K-832-silica DCM). Scanning electron microscopy, polarizing microscopy, differential scanning calorimetry, and powder X-ray diffraction observations revealed that in both formulations, K-832 existed mainly in an amorphous state. In a dissolution test, 70.2% and 13.3% of K-832 were released from K-832-silica scCO(2) and K-832-silica DCM, respectively, within 5min, whereas only 2.3% of K-832 was released from a physical mixture within 120min. Results of an in vivo absorption test showed that the area under the plasma concentration-time curve and peak concentration of K-832-silica scCO(2) were 8.3- and 13.3-fold greater than those of K-832 crystal, whereas the corresponding values of K-832-silica DCM were 5.0- and 8.3-fold greater than those of K-832 crystal. These results suggest that the method of using scCO(2) as the solvent is effective in enhancing the dissolution rate and oral absorption of poorly water-soluble drugs because it does not require a toxic solvent and surfactant.


Colloids and Surfaces B: Biointerfaces | 2009

Preparation and properties of carrageenan microspheres containing allopurinol and local anesthetic agents for the treatment of oral mucositis

Keishiro Tomoda; Masato Asahiyama; Emi Ohtsuki; Takehisa Nakajima; Hiroshi Terada; Makoto Kanebako; Toshio Inagi; Kimiko Makino

For the treatment of oral mucositis, carrageenan microspheres containing allopurinol and local anesthetic agents, such as lidocaine hydrochloride, dibucaine hydrochloride and tetracaine hydrochloride were prepared using a spray-drying method. As base materials, kappa-carrageenan and iota-carrageenan were evaluated, since carrageenan mitigates bitter taste of lidocaine hydrochloride, dibucaine hydrochloride and tetracaine hydrochloride. The microspheres were spherical and their average diameters were about 10 microm. The drug loading efficiency was more than 70%. Allopurinol and local anesthetic agents became amorphous by the spray drying. Allopurinol and the local anesthetic agents were released from the microspheres for at least 400 min when iota-carrageenan was used as a base material. On the other hand, the release was prolonged to 600 min when kappa-carrageenan was used. The microspheres were spread and made membranes at the air/water interfaces immediately after dropped on the water surfaces. The properties of the microspheres such as dispersing efficacy and membrane production on the water surfaces suggest that the microspheres can uniformly cover inner surfaces of oral cavity to prevent and treat oral mucositis.


International Journal of Pharmaceutics | 2011

Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state 13C NMR spectroscopy

Hiroshi Miura; Makoto Kanebako; Hiroyuki Shirai; Hiroshi Nakao; Toshio Inagi; Katsuhide Terada

This study evaluated the physical stability and molecular mobility of a poorly water-soluble amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one (K-832), adsorbed onto silica mesopores. K-832-Sylysia 740 and K-832-Sylysia 350 formulations, prepared by adsorbing K-832 onto porous silica Sylysia 740 (2.5-nm-diameter pores) and Sylysia 350 (21-nm-diameter pores) and stored at 60°C/80%RH (open and closed conditions), were investigated. Differential scanning calorimetry revealed that crystallization of K-832 in the K-832-Sylysia 350 formulation stored at 60°C/80%RH (open and closed conditions) was faster than that of the other formulation stored under identical conditions. Raman spectroscopy revealed shifts to higher wavenumbers in the K-832-Sylysia 350 and K-832-Sylysia 740 formulations (1497 and 1493 cm(-1), respectively) in comparison to amorphous K-832 (1481 cm(-1)); however, no distinct differences were observed in the spectra of the two formulations. Solid-state (13)C NMR spectroscopy revealed a difference in spin-lattice relaxation time in the rotating frame (T(1ρ)) between the two formulations, suggesting the lower molecular mobility of K-832 in the 2.5-nm-diameter pores than in the 21-nm-diameter pores. Thus, the crystallization rate of amorphous K-832 in the K-832-Sylysia 740 formulation was much slower. These results will be useful in estimating the physical stability of amorphous drugs in mesopores.


Journal of Controlled Release | 2013

Novel iontophoretic administration method for local therapy of breast cancer

Masahito Komuro; Kenichi Suzuki; Makoto Kanebako; Takashi Kawahara; Takeshige Otoi; Kenji Kitazato; Toshio Inagi; Kimiko Makino; Masakazu Toi; Hiroshi Terada

Ductal drug therapy is a novel therapeutic approach for primary breast cancers, particularly those involving ductal carcinoma in situ lesions. Total or partial mastectomy with or without radiotherapy is the standard local therapy for primary breast cancer. Here, we propose a novel drug administration method for ductal drug therapy based on a drug delivery system (DDS) for primary breast cancer. This DDS was designed to deliver miproxifen phosphate (TAT-59), an antiestrogen drug, to ductal lesions via the milk duct, where carcinomas originate, more efficiently than systemic administration, using an iontophoretic technique applied to the nipple (IP administration). Autoradiography imaging confirmed that TAT-59 was directly delivered to the milk duct using IP administration. The plasma concentrations of TAT-59 and its active metabolite DP-TAT-59 were quite low with IP administration. The area under the curve value of DP-TAT-59 in the mammary tissue was approximately 3 times higher with IP administration than with oral administration, at a 6-fold lower dose, indicating higher availability of the drug delivered via DDS than via systemic administration. The low plasma concentrations would limit adverse effects to minor ones. These characteristics show that this DDS is suitable for the delivery of active DP-TAT-59 to ductal lesions.


Archive | 1998

Device for iontophoresis

Makoto Kanebako; Toshio Inagi; Makoto Haga; Masahiro Hayashi


Biological & Pharmaceutical Bulletin | 2002

Transdermal Delivery of Indomethacin by Iontophoresis

Makoto Kanebako; Toshio Inagi; Kozo Takayama


Archive | 1996

Adhesive base material

Toshio Inagi; Makoto Kanebako


Chemical & Pharmaceutical Bulletin | 2011

Influence of Particle Design on Oral Absorption of Poorly Water-Soluble Drug in a Silica Particle–Supercritical Fluid System

Hiroshi Miura; Makoto Kanebako; Hiroyuki Shirai; Hiroshi Nakao; Toshio Inagi; Katsuhide Terada


Archive | 2004

COMPOSITION CONTAINING MEDICINE EXTREMELY SLIGHTLY SOLUBLE IN WATER AND METHOD FOR PREPARATION THEREOF

Hiroshi Miura; Makoto Kanebako; Masayuki Kanishi; Yasuo Shinoda; Toshio Inagi; Hirofumi Takeuchi


Biological & Pharmaceutical Bulletin | 2002

Evaluation of Skin Barrier Function Using Direct Current II: Effects of Duty Cycle, Waveform, Frequency and Mode

Makoto Kanebako; Toshio Inagi; Kozo Takayama

Collaboration


Dive into the Makoto Kanebako's collaboration.

Top Co-Authors

Avatar

Toshio Inagi

University of Tokushima

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenichi Suzuki

Tokyo Electric Power Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroshi Terada

Tokyo University of Science

View shared research outputs
Top Co-Authors

Avatar

Kimiko Makino

Tokyo University of Science

View shared research outputs
Top Co-Authors

Avatar

Emi Ohtsuki

Tokyo University of Science

View shared research outputs
Researchain Logo
Decentralizing Knowledge